Virax Biolabs Group Long Term Debt

Virax Biolabs Group (VRAX) currently reports a long-term debt of $300K as of March 2026. That compares with $290K in the prior-year period — up 4.5% year over year. Use the charts on this page to explore Virax Biolabs Group's long-term debt history and peer comparisons.

Virax Biolabs Group's long-term debt increased from $290K to $300K — a 4.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Virax Biolabs Group reported $300K in long-term debt as of March 2026. That compares with $290K in the prior-year period — up 4.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $300K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Virax Biolabs Group, and consider following VRAX for alerts when major investors trade the stock.